Brain Tumor, Primary Clinical Trial
Official title:
Immunophenotype Characterization of Circulating and Tumor Infiltrating Immune Cells in Malignant Brain Tumors.
The goal of this observational study is to characterize the circulating leukocyte profile and the immune T cells distribution within the tumor in patients with malignant brain tumors and to correlate these findings with the oncological outcome. Participants will be subjected to blood sampling before surgery and for 12 months of follow-up. Additional sampling and analysis will be performed on tumor samples.
High-grade gliomas are the most frequent type of primary brain tumor in adults, and among them, glioblastoma multiforme (GBM) is the most malignant with an associated poor prognosis. Although significant advances have been achieved in GBM biology comprehension, patients' life expectancy is still limited to 18 months. Brain metastases (BM) are the most frequent neoplasm in the CNS; it is estimated that up to 14% of all newly diagnosed cancers will soon or later metastasize into the brain. A variety of mechanisms to escape a tumor-specific T cell-mediated immune response have been identified in glioma and other cancer entities. This project is an observational, prospective, monocentric study on patients candidates for neurosurgical procedures for brain malignant tumors with additional collection of biological material. With the present study, we aim to characterize the phenotype of both circulating- and tumor-infiltrating- immune cells at the diagnosis and their changes during disease progression and after treatment in primary and secondary brain tumors. Samples will be taken at baseline (before surgery) and at time-points: 3, 6, 9, 12 months ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06057168 -
Performance of Elucirem® in DSC-MRI Perfusion of Brain Gliomas
|
Phase 3 | |
| Recruiting |
NCT04427384 -
Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)
|
||
| Completed |
NCT03323450 -
Cognitive Remediation Therapy for Brain Tumor Patients: Improving Working Memory
|
N/A | |
| Completed |
NCT00241670 -
Fluorescence-guided Resection of Malignant Gliomas With 5-Aminolevulinic Acid
|
Phase 3 | |
| Not yet recruiting |
NCT01445691 -
More Complete Removal of Malignant Brain Tumors by Fluorescence-Guided Surgery
|
Phase 2 | |
| Completed |
NCT02599142 -
Comparing Immobilisation Shells in Cranial Radiotherapy
|
N/A | |
| Recruiting |
NCT06282562 -
FeelFit: High-intensity Interval Training to Improve Self-reported Physical Fitness in Brain Tumor Patients
|
N/A | |
| Completed |
NCT00001574 -
A Pilot Study of 1H-Nuclear Magnetic Resonance Spectroscopic Imaging in Pediatric Patients With Primary and Metastatic Brain Tumors
|
||
| Completed |
NCT04365647 -
Intra-operative Variation in Size of Brain Tumors After Craniotomy
|
||
| Withdrawn |
NCT04776980 -
Multimodality MRI and Liquid Biopsy in GBM
|
Early Phase 1 | |
| Completed |
NCT03262636 -
Two-Part Study to Evaluate the Safety and Efficacy of Image Guided Surgery Using Indocyanine Green for Intramolecular Imaging of Nervous System Tumors Compared to Standard of Care, (TumorGlow)
|
Phase 1 | |
| Active, not recruiting |
NCT02006407 -
A Pilot Study to Evaluate Neurocognitive Injury and Longitudinal Changes in White Matter During Radiation Therapy in Children With Primary Brain Tumors
|
N/A | |
| Recruiting |
NCT03213002 -
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05775458 -
Glutamate Excitotoxicity and Its Role in Glioblastoma Biology
|
||
| Terminated |
NCT04901806 -
Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT03373487 -
Cognitive Rehabilitation in Brain Tumor Patients After Neurosurgery
|
N/A | |
| Not yet recruiting |
NCT06106997 -
Clinical Feasibility of Brain Radiotherapy Using Synthetic CTs in an MRI-only Workflow
|
N/A | |
| Recruiting |
NCT05254197 -
SeOuL cOhort of Brain Tumor MONitoring Study (SOLOMON)
|
||
| Recruiting |
NCT05092802 -
The Efficacy of HLX208 (BRAF V600E Inhibitor) for Refractory Primary Brain Tumors With BRAF Mutation After First-line Treatment
|
Phase 2 | |
| Recruiting |
NCT05480644 -
Circulating Biomarkers Repository in Adults Diagnosed With Primary and Metastatic Brain Tumors
|